Therapies targeting tyrosine kinases that block BCR-ABL transcript expression are the most promising strategies for treating patients with CML who are ineligible for bone marrow transplantation as a treatment. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.